Recent Research Analysts’ Ratings Updates for Aspira Women’s Health (AWH)

A number of firms have modified their ratings and price targets on shares of Aspira Women’s Health (NASDAQ: AWH) recently:

• 4/10/2024 – Aspira Women’s Health had its “neutral” rating reaffirmed by analysts at Cantor Fitzgerald. They now have a $3.30 price target on the stock.
• 4/3/2024 – Aspira Women’s Health was upgraded by analysts at StockNews.com from a “sell” rating to a “hold” rating.
• 4/1/2024 – Aspira Women’s Health had its price target lowered by analysts at Cantor Fitzgerald from $4.00 to $3.30. They now have a “neutral” rating on the stock.
• 3/28/2024 – Aspira Women’s Health was downgraded by analysts at StockNews.com from a “hold” rating to a “sell” rating.
• 3/22/2024 – Aspira Women’s Health was downgraded by analysts at StockNews.com from a “hold” rating to a “sell” rating.

Aspira Women’s Health Price Performance

NASDAQ AWH opened at $3.49 on Thursday. The stock has a market capitalization of $43.07 million, a price-to-earnings ratio of -0.29 and a beta of 1.61. Aspira Women’s Health Inc. has a one year low of $2.31 and a one year high of $6.75. The business’s fifty day moving average is $3.77 and its 200-day moving average is $4.08.

Institutional Investors Weigh In On Aspira Women’s Health

Hedge funds have recently made changes to their positions in the business. Northeast Financial Consultants Inc bought a new stake in shares of Aspira Women’s Health during the third quarter valued at about $126,000. Northern Trust Corp grew its position in Aspira Women’s Health by 227.7% during the fourth quarter. Northern Trust Corp now owns 36,049 shares of the company’s stock valued at $147,000 after acquiring an additional 25,047 shares during the last quarter. Atria Wealth Solutions Inc. bought a new position in Aspira Women’s Health during the first quarter valued at approximately $49,000. Perkins Capital Management Inc. bought a new position in Aspira Women’s Health during the third quarter valued at approximately $268,000. Finally, Quantum Private Wealth LLC boosted its stake in shares of Aspira Women’s Health by 76.8% during the fourth quarter. Quantum Private Wealth LLC now owns 50,156 shares of the company’s stock valued at $205,000 after purchasing an additional 21,788 shares during the period. 12.19% of the stock is currently owned by institutional investors.

Aspira Women's Health Inc, together with its subsidiaries, engages in developing and commercializing diagnostic tests for gynecologic disease in the United States. The company's products include Ova1, a blood test intended as an aid to further assess the likelihood of malignancy in women with an ovarian adnexal mass; Overa, a biomarker reflex test; and Ova1Plus, a reflex offering.